Alcon (2U3) AI Stock Analysis

4 Followers

Alcon

(XETRA:2U3)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Recurring, diversified eye-care modelAlcon's two-segment model combines procedure-linked surgical consumables with contact lenses and ocular-health products. Its surgical equipment installed base can generate repeat consumables, service, and upgrade demand, while lens replacement cycles add recurring purchasing and revenue resilience.

Negative Factors

Recent profitability and return deteriorationRecent earnings quality has weakened despite steady sales and a healthy gross-margin base. TTM net margin fell to about 5.9% from roughly 9%–10% in 2024–2025, operating profitability also declined, and ROE fell to about 2.9%, reducing current earnings efficiency.

Alcon (2U3) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 35.03B
Dividend Yield: 0.48%
Average Volume (3M): 3,474
Price to Earnings (P/E): 55.7
Beta (1Y): 0.81
Revenue Growth: 2.52%
EPS Growth: -38.86%
Country: Germany
Employees: 25,942
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Specialties

Alcon Business Overview & Revenue Model

Company Description

Alcon Inc. is a global eye care enterprise dedicated to the research, development, manufacturing, and distribution of a comprehensive range of vision products for both eye care professionals and their patients worldwide. The company operates through...

Alcon Earnings Call Summary

Earnings Call Date:Nov 10, 2026(Q3-2026)|% Change Since:-4.31%|Next Earnings Date:Mar 02, 2027

Earnings Call SentimentPositive

The call was broadly positive. Alcon delivered 5% quarterly sales growth, 6% year-to-date growth, 15% core EPS growth, strong free cash flow and meaningful capital returns, while reporting momentum in equipment, contact lenses, ocular health and new product launches. The company also highlighted a broad innovation pipeline, the Neurotech acquisition and continued efficiency initiatives. The main negatives were competitive pressure in U.S. premium IOLs, softer international contact lens conditions, eye care markets at the low end of expectations, narrowed 2026 profitability guidance and several identified 2027 headwinds.

Positive Updates

Third-Quarter Sales Growth and Full-Year Execution

Third-quarter sales grew 5% to $2.7 billion, with year-to-date sales growth of 6%. Alcon remains on track for approximately 6% sales growth and double-digit core EPS growth for 2026.

Negative Updates

Competitive Pressure in Implantables

Implantable sales declined 2% year-over-year to $422 million, with IOL sales down 1%. The decline was driven primarily by competitive launches in the U.S. premium IOL category, continued competitive trialing and sampling, and reimbursement challenges for dual procedures in glaucoma implants.

Company Guidance

For 2026, Alcon expects sales growth of approximately 6%, core operating margin expansion of 100 to 150 basis points, and core diluted EPS growth of 12% to 14%, assuming aggregate eye care markets grew 3% for the year, exchange rates as of the end of October hold through year-end, and U.S. import tariff rates of approximately 10% to 12.5% remain in effect through year-end. For 2027, the base case assumes current market trends persist, with another year of above-market sales growth, Neurotech adding approximately 75 to 100 basis points to the top line, and roughly 150 to 200 basis points of gross operating leverage before the $60 million in tariff refunds, a $15 million milestone payment, incremental inflation related to memory and resins, and near-term pressure from the Neurotech acquisition; Alcon continues to expect margin improvement in 2027 and will issue formal guidance in February. The long-term 6% to 8% constant currency growth guide remains in place, but Alcon expects to be at the low end of that guide.

Alcon Risk Analysis

Alcon disclosed 40 risk factors in its most recent earnings report. Alcon reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Alcon Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:2U3 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CH:ROP	81Outperform	CHF 320.60B	26.16	37.12%	2.44%	-1.06%	30.86%
CH:STMN	72Outperform	CHF 17.04B	45.77	―	0.94%	2.24%	-5.84%
CH:SFZN	67Neutral	CHF 3.22B	18.26	16.14%	0.56%	3.64%	10.93%
CH:TECN	63Neutral	CHF 3.31B	-28.43	-10.25%	1.15%	-3.98%	-284.91%
CH:MEDX	58Neutral	CHF 431.60M	4176.00	―	0.96%	-6.64%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:2U3 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:2U3	Alcon	64.36	-3.53	-5.20%
CH:ROP	Roche Holding	401.90	120.61	42.88%
CH:STMN	Straumann Holding	106.65	5.87	5.83%
CH:SFZN	Siegfried Holding AG	71.40	-4.31	-5.69%
CH:TECN	Tecan Group AG	260.40	121.84	87.93%
CH:MEDX	medmix AG	10.44	1.77	20.37%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Alcon AI Stock Analysis